

Supplementary table 1. Baseline characteristics of 935 patients with low and intermediate non-muscle invasive bladder cancer, without information on tumour size and/or tumour multiplicity.

	n (%)
Number of patients	935
Median age [interquartile range] years	73 [66-79]
Sex	
Female	213 (23)
Male	722 (77)
Tumor stage	
Ta	774 (83)
T1	161 (17)
Grade (WHO 1999)	
G1	437 (47)
G2	498 (53)

WHO=World Health Organization

Supplementary table 2. Baseline characteristics for the 152 patients with primary intermediate risk (IR) non-muscle invasive bladder cancer receiving adjuvant serial instillations and stratified into low- and intermediate-IR.

	Low n (%)	Intermediate n (%)	Total n (%)
Number of patients	72	80	152
Median age [interquartile range] years	70 [62-75]	70 [66-76]	70 [62-76]
Sex			
Female	19 (13)	22 (14)	41 (27)
Male	53 (35)	58 (38)	111 (73)
Tumor size			
0-3 cm	72 (47)	37 (24)	109 (72)
≥ 3 cm	0 (0)	43 (28)	43 (28)
Multiplicity			
Single	72 (47)	30 (20)	102 (67)
Multiple	0 (0)	50 (33)	50 (33)
Tumor stage			
Ta	55 (36)	79 (52)	134 (88)
T1	17 (11)	1 (0.7)	18 (12)
Grade (WHO 1999)			
G1	1 (0.7)	15 (10)	16 (11)
G2	71 (47)	65 (43)	136 (89)
Single postoperative instillation	2 (1)	5 (3)	7 (5)

WHO=World Health Organization

Supplementary table 3a. Baseline characteristics for the 558 patients with intermediate risk non-muscle invasive bladder cancer not receiving adjuvant serial instillations and stratified into low- and intermediate-IR.

	Low n (%)	Intermediate n (%)	Total n (%)
Number of patients	257	301	558
Median age [interquartile range] years	72 [66-80]	75 [70-82]	74 [67-81]
Sex			
Female	52 (9)	78 (14)	130 (23)
Male	205 (37)	223 (40)	428 (77)
Tumor size			
0-3 cm	257 (46)	156 (28)	413 (74)
≥ 3 cm	0 (0)	145 (26)	145 (26)
Multiplicity			
Single	257 (46)	117 (21)	374 (67)
Multiple	0 (0)	184 (33)	184 (33)
Tumor stage			
Ta	251 (45)	299 (54)	550 (99)
T1	6 (1)	2 (0.4)	8 (1)
Grade (WHO 1999)			
G1	1 (0.2)	135 (24)	136 (24)
G2	256 (46)	166 (30)	422 (76)
Single postoperative instillation	11 (2)	20 (4)	31 (6)

Supplementary table 3b. Probability of recurrence at one and three years after diagnosis of primary intermediate risk (IR) non-muscle invasive bladder cancer of the 558 patients not receiving adjuvant serial instillations stratified into low- and intermediate-IR.

Recurrence probability (% (95% confidence interval))		
	One year	Three years
Low-IR	19 (14-24)	43 (36-49)
Intermediate-IR	30 (24-35)	49 (43-55)

WHO=World Health Organization